Physicians' Academy for Cardiovascular Education

PCSK9

UP TO DATE: Follow news, literature and expert perspectives on PCSK9 inhibition in lipid management

PCSK9i reduces plaque burden in coronary arteries

3' education - Apr. 6, 2022 - Prof. Lorenz Räber, MD, PhD
Experts in dialogue - LDL-c goal attainment in high risk patients

What are current challenges and barriers in achieving LDL-c goals?

15' education - Apr. 13, 2021 - Prof. Lale Tokgözoğlu, MD and prof. Kausik Ray, MD - Online CME
Experts in dialogue - LDL-c goal attainment in high risk patients

The gap between guideline LDL-c goals and current practice: How are we doing?

15' education - Apr. 1, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD - Online CME
Experts in dialogue - LDL-c goal attainment in high risk patients

The proven case for LDL-c lowering

15' education - Mar. 26, 2021 - Prof. Kausik Ray, MD and prof. John Kastelein, MD, PhD

Introduction: PCSK9i & LDL-c - Guidelines, Practice & Innovation

10' education - Nov. 9, 2020 - Prof. John Kastelein, MD

Time to reduce implementation gaps of lipid-lowering therapy

10' education - Nov. 6, 2020 - Prof. Kausik Ray, MD - Online CME

Is there a role for PCSK9 inhibition in patients with high Lp(a)?

10' education - Nov. 2, 2020 - Prof. Vera Bittner, MD - Online CME

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD

Small interfering RNA against PCSK9 reduces LDL-c in HeFH independent of genotype

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD

Five years of PCSK9i - Lessons from practice: Which patients benefit most?

10' education - Sep. 30, 2020 - Prof. Erik Stroes, MD - Online CME

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

One year after the new ESC/EAS dyslipidemia guidelines

10' education - Sep. 17, 2020 - Prof. François Mach - Online CME

Treatment goals for LDL-c-lowering and emerging evidence for the importance of Lp(a)

10' education - May 26, 2020 - Prof. J. Wouter Jukema, MD - Leiden, The Netherlands

One step closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 9, 2020 - Dirk Blom, PhD

Addressing lipid risk: a system-wide approach to implementation

5' education - Feb. 27, 2020 - Jorge Plutzky, MD

Patient-reported cognition at the end of a PCSK9 antibody trial

5' education - Nov. 17, 2019 - Baris Gencer, MD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

Treatment benefit with PCSK9 antibody in patients with recent vs. remote MI

5' education - Feb. 2, 2020 - Baris Gencer, MD

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients?

10' education - Sep. 24, 2019 - Prof. Marc S. Sabatine, MD

Targeting PCSK9: Expanding knowledge and targeting new frontiers

10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD

Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS

5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach

Positive phase II trial data with novel anti-PCSK9 agent

3' education - May 29, 2019 - Maastricht, The Netherlands - Prof. Evan Stein, MD

Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction

3' education - May 29, 2019 - Maastricht. The Netherlands - Prof. Chapman, DSc

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME

PCSK9i reduces MACE regardless of number of metabolic risk factors

Literature - May 16, 2022 - Ostadal P, et al. - Lancet Diabetes Endocrinol. 2022

Alirocumab reduces MACE irrespective of number of metabolic risk factors, but absolute risk reduction increases with the number of metabolic risk factors, in a post-hoc analysis of ODYSSEY OUTCOMES

Sustained LDL-c lowering with PCSK9 siRNA in patients with prior MI

News - Apr. 19, 2022

ACC 2022 A post hoc pooled analysis from the ORION-10 and ORION-11 trials showed that inclisiran, compared with placebo, in addition to statin and/or ezetimibe provided effective and sustained LDL-c lowering in patients with prior MI.

PCSK9i reduces plaque burden in coronary arteries

3' education - Apr. 6, 2022 - Prof. Lorenz Räber, MD, PhD
ACS patients frequently harbor vulnerable plaques in non-infarct related coronary arteries. The PACMAN AMI study investigated to which degree vulnerable plaques can regress and stabilize in patients receiving alirocumab on top of high-intensity statin.

ACC 2022 ACS patients frequently harbor vulnerable plaques in non-infarct related coronary arteries. The PACMAN AMI study investigated to which degree vulnerable plaques can regress and stabilize in patients receiving alirocumab on top of high-intensity statin.

Greater plaque regression and stabilization with PCSK9i in patients with acute MI

News - Apr. 4, 2022

ACC 2022 Treatment with alirocumab, compared with placebo, in addition to high-intensity statin therapy resulted in greater coronary plaque regression, greater cholesterol core reduction and a higher increase of the protective fibrous cap thickness in patients with acute MI.

PCSK9i reduces MACE and coronary revascularization in patients with prior PCI

Literature - Mar. 2, 2022 - Furtado RHM, et al. - Circ Cardiovasc Interv 2022

In a prespecified subgroup analysis of the FOURIER trial, evolocumab reduces MACE and coronary revascularization in patients prior PCI at baseline with consistent reductions in a broad range of lesion types

No reduction of MACE with PCSK9i in patients with a history of HF

Literature - Jan. 25, 2022 - White HD, et al. - Eur Heart J 2021

Although alirocumab reduced LDL-c in patients with or without a history of HF, alirocumab reduced MACE only in patients without HF and not in patients with a history of HF, in an analysis of ODYSSEY OUTCOMES.

Oral PCSK9 inhibitor effectively lowers LDL-c

News - Nov. 16, 2021

AHA 2021 Two phase I studies report the safety and effectiveness of MK-0616, a new oral PCSK9 inhibitor. MK-0616 lowered free PCSK9 in the blood by ≥90% and reduced LDL-c by ~65% after 14 days of treatment, compared to baseline.

Acute arterial events reduced by PCSK9 inhibitor across all vascular territories

Literature - Oct. 14, 2021 - Oyama K, et al. - Eur Heart J 2021

Treatment with the PCSK9 inhibitor evolocumab in high CV risk patients reduced the risk of acute arterial events across all vascular territories, as shown in a post hoc analysis of FOURIER.

E-learning Redefining intensive LDL-c management in high CV risk patients – The case for combination therapy

Accredited E-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

Real-world evidence shows that the majority of patients do not achieve their LDL-c target goals. Where do we fall short in the need for combination therapy?

Continued efficacy of LDL-c lowering, even below 40 mg/dL, in high risk patients

Literature - Sep. 8, 2021 - Marston NA et al. - Circulation 2021

An exploratory analysis of FOURIER showed that lowering of LDL-c by evolocumab below 40 mg/dL resulted in continued reduction of MACE in ASCVD patients.

NHS agreement on population health management approach using PCSK9 siRNA therapy

News - Sep. 7, 2021

The NHS has made an agreement on a population health management approach in those eligible for the PCSK9 siRNA inclisiran.

PCSK9 siRNA reduces LDL-c in patients with and without polyvascular disease

News - Sep. 6, 2021

ESC 2021 This pooled, post-hoc analysis of ORION-9, -10, and -11 showed that inclisiran significantly reduced LDL-c compared placebo in patients with and without polyvascular disease.

PCSK9